Document is current
Any future updates will be listed below
-
Authors
Martín, Teresa
Miravitlles, Marc
- License Information
-
More Information
Article History
Received: 26 October 2024
Accepted: 6 December 2024
First Online: 24 January 2025
Declarations
:
: Not applicable.
: Not applicable.
: Teresa Martín has received speaker fees from AstraZeneca CSL Behring, and GlaxoSmithKline, consulting fees from GlaxoSmithKline, and support for attending meetings from AstraZeneca, Bial, Boehringer Ingelheim, CSL Behring, Novartis, Medinfar, Tecnimede and Pfizer. Marc Miravitlles has received speaker fees from AstraZeneca, Boehringer Ingelheim, Kamada, Chiesi, Cipla, Menarini, Rovi, Bial, Sandoz, Takeda, Zambon, CSL Behring, Specialty Therapeutics, Grifols and Novartis, consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, Kamada, CSL Behring, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, TEVA, Spin Therapeutics, pH Pharma, Novartis, Sanofi and Grifols and research grants from Grifols.
